Effect of Lifestyle Intervention in Patients With Chronic Kidney Disease on Fitness and Immune Function

December 12, 2022 updated by: Chang Gung Memorial Hospital
To assess the efficacy of a 6-month lifestyle intervention in patients with CKD, we plan to conduct a self-controlled clinical trial. 120 participants with CKD stage 3-5 will be enrolled. In addition, 20 participants with CKD stages 1 and 2 respectively, and 20 healthy subjects will be recruited; they will receive physical fitness and immune function assessment once; no intervention will be given. The participants with 3-5 CKD will go through three phases: 3-month control, 6-month intervention, and 3-month maintenance. No intervention will be performed in the control and maintenance phases. The lifestyle intervention will comprise care from a multidisciplinary team, including a nephrologist, nurse practitioner, physiatrist, and dietitian. The exercise training component will offer two options for the participants to choose from. First, a two-week individualized and supervised center-based exercise intervention followed by 6 months of a home-based program with refresher visits once per month. The participant will be requested to wear a heart rate recorder during home exercise. Second, persistent in-hospital training 2~3 times weekly for 6 months. Cyclic aerobic and resistance training will be performed. Assessment will be performed every three months and 5 times in total, including cardiopulmonary exercise testing, isokinetic quadriceps strength testing, hand grip strength, body composition analysis, Chinese Kidney Disease and Quality of Life questionnaire, self-recorded physical activity, and Mini Nutritional Assessment. The aim of this study is to assess the efficacy of a lifestyle intervention in patients with CKD on physical fitness, quality of life, and immunity. It is hypothesized that the lifestyle intervention will elicit a significant benefit in the aforementioned parameters and will last until the maintenance phase.

Study Overview

Status

Recruiting

Detailed Description

The prevalence of chronic kidney disease (CKD) in stages 3~5 is as high as 11.6% in Taiwan. Cardiovascular diseases and infection are the major causes of morbidity. Though evidence is clear that exercise training in this population is beneficial to fitness、quality of life、morbidity, it is seriously underused. Poor physical fitness is known to associate with high-leveled systemic inflammation and immune dysregulation but the detailed relationship remains unclear in the CKD population. Moreover, though exercise improves low physical fitness, available research concerning its effect on the pro-/anti-inflammatory immune response is scarce. Does supervised lifestyle intervention has the potential to improve physical fitness, quality of life and immunity in patients with chronic kidney disease (CKD)? To assess the efficacy of a 6-month lifestyle intervention in patients with CKD, we plan to conduct a self-controlled clinical trial. 120 participants with CKD stage 3-5 will be enrolled. In addition, 20 participants with CKD stages 1 and 2 respectively, and 20 healthy subjects will be recruited; they will receive physical fitness and immune function assessment once; no intervention will be given. The participants with 3-5 CKD will go through three phases: 3-month control, 6-month intervention, and 3-month maintenance. No intervention will be performed in the control and maintenance phases. The lifestyle intervention will comprise care from a multidisciplinary team, including a nephrologist, nurse practitioner, physiatrist, and dietitian. The exercise training component will offer two options for the participants to choose from. First, a two-week individualized and supervised center-based exercise intervention followed by 6 months of a home-based program with refresher visits once per month. The participant will be requested to wear a heart rate recorder during home exercise. Second, persistent in-hospital training 2~3 times weekly for 6 months. Cyclic aerobic and resistance training will be performed. Assessment will be performed every three months and 5 times in total, including cardiopulmonary exercise testing, isokinetic quadriceps strength testing, hand grip strength, body composition analysis, Chinese Kidney Disease and Quality of Life questionnaire, self-recorded physical activity, and Mini Nutritional Assessment. The aim of this study is to assess the efficacy of a lifestyle intervention in patients with CKD on physical fitness, quality of life, and immunity. It is hypothesized that the lifestyle intervention will elicit a significant benefit in the aforementioned parameters and will last until the maintenance phase. The goal for each year is as follows. The FIRST year: To explore the relationship between physical fitness and pro-/anti-inflammatory immune response in different stages of CKD patients; the SECOND year: to assess the effect of lifestyle intervention on physical fitness, QOL, sedentary time, and nutrition status; the THIRD year: To evaluate the effects of lifestyle intervention on immunity.

Study Type

Interventional

Enrollment (Anticipated)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Taoyuan, Taiwan, 333
        • Recruiting
        • Chang Gung memorial hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients with CKD in stages 3-5
  • patients who are on HD for longer than 6 months
  • under the permission of their nephrologist
  • adequately dialyzed (most recent Kt/V > 1.2) and stable during dialysis in the past 3 months

Exclusion Criteria:

  • occurrence of hyperkalemia in the past 3 months
  • comorbid medical, physical, and mental conditions that contraindicate exercise
  • unstable cardiac conditions (eg, unstable angina, heart failure or symptomatic severe aortic stenosis, etc.)
  • disabling orthopedic and neuromuscular diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CKD patients with exercise training intervention
The participants with 3-5 CKD will go through three phases: 3-month control, 6-month intervention, and 3-month maintenance. No intervention will be performed in the control and maintenance phases
Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2~3 sessions per week and about 70 sessions in total.
No Intervention: CKD stage 1 and 2
no inervention
No Intervention: CKD stage 1 and 2 respectively, and 20 healthy subjects
no inervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exercise capacity of all participants by Cardiopulmonary Exercise Test (CPET)
Time Frame: three years
Cardiopulmonary Exercise Test cardiopulmonary exercise test.
three years
To examine the levels of inflammatory chemokines in the circulation of participants by Luminex assay
Time Frame: three years
Luminex assay
three years
To detect the levels of anti-inflammatory microRNAs in the circulation of participants by qPCR
Time Frame: three years
qPCR
three years
To study various populations of immune cells in the circulation of patients
Time Frame: three years
flow cytometry
three years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the association between fitness and immune responses by the questionnaire of Hong Kong Chinese Kidney Disease and Quality of Life
Time Frame: three years
The minimum and maximum values of the Hong Kong Chinese Kidney Disease and Quality of Life questionnaire are 0 and 100, separately. The higher scores mean a better outcome.
three years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shu-Chun Huang, MD, PhD, Chang Gung memorial hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 20, 2022

Primary Completion (Anticipated)

September 18, 2024

Study Completion (Anticipated)

September 18, 2025

Study Registration Dates

First Submitted

November 7, 2022

First Submitted That Met QC Criteria

December 12, 2022

First Posted (Actual)

December 14, 2022

Study Record Updates

Last Update Posted (Actual)

December 14, 2022

Last Update Submitted That Met QC Criteria

December 12, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 202201244B0A3

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Diseases

Clinical Trials on Cyclic aerobic and resistance training

3
Subscribe